SEPTERNA INC (SEPN)
SEPTERNA INC
NASDAQ:SEPN (11/20/2024, 8:00:02 PM)
After market: 22.5 0 (0%)22.5
-1.7 (-7.02%)
Company Profile
Septerna Inc is a US-based company operating in industry. The company is headquartered in South San Francisco, California. The company went IPO on 2024-10-25. Septerna, Inc. is a clinical-stage biotechnology company. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. The company is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Company Info
SEPTERNA INC
250 East Grand Avenue, Suite 65
South San Francisco CALIFORNIA
P: 16503383533
Employees: 0
Website: https://septerna.com/
SEPN News
22 hours ago - Septerna, Inc.Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights22 hours ago - Septerna, Inc.Septerna Reports Third Quarter 2024 Financial Results and Recent Business HighlightsDeep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical...
22 days ago - Septerna, Inc.Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering22 days ago - Septerna, Inc.Septerna Announces Closing of $331.2 Million Upsized Initial Public OfferingSOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era...
a month ago - BloombergSepterna Shares Jump 42% After IPO Shows Biotech Still HotSepterna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an enlarged initial public offering.
a month ago - Septerna, Inc.Septerna Prices Upsized Initial Public OfferingSEPN Twits
Here you can normally see the latest stock twits on SEPN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
